Table 5.
Gene | Function | Amygdala | HC | Prefrontal cortex | Thalamus | ||||
---|---|---|---|---|---|---|---|---|---|
fc | P-value | fc | P-value | fc | P-value | fc | P-value | ||
CALB2* | Neurogenesis; neuroplasticity | 2.17 | 0.01 | ||||||
CLIC6* | Inhibitory neurotransmission; spatial learning and neuroplasticity | 1.72 | 0.01 | ||||||
CX3CR1* | Neuroinflammation | 2.96 | 0.001 | 2.34 | 0.01 | 3.78 | 0.001 | ||
CHRNA6* | Motivation, addiction and motor disorders | 1.9 | 0.01 | ||||||
C3* | Microglia-dependent synaptic plasticity | 2.24 | 0.001 | 2.34 | 0.01 | 3.78 | 0.001 | ||
ENPP1* | Maintenance of stem cell phenotype | 1.75 | 0.001 | ||||||
GFAP* | Neuroinflammation; major depression (MDD) and schizophrenia | 1.92 | 0.001 | ||||||
MIR548H2** | microRNA, regulation of stability and translation of mRNA | − 2.73 | 0.001 | ||||||
NEXN* | Neuroplasticity through cytoskeleton, signal transduction at the neurovascular unit | 1.84 | 0.01 | ||||||
PARM1* | Potential oncogene; prognostic biomarker for colorectal cancer | 1.95 | 0.001 | 1.71 | 0.001 | ||||
RAB3B* | Long-term depression; short-term plasticity; normal reversal learning | 2.13 | 0.01 | ||||||
RNU4-2* | RNA, U4 small nuclear 2 | 1.93 | 0.01 | 2.15 | 0.01 | 1.85 | 0.01 | 2.30 | 0.01 |
RNU6ATAC* | Cellular stress; aggressive neuroblastoma | − 1.77 | 0.01 | ||||||
RNU7-53P* | Diabetes and related traits | − 1.82 | 0.01 | ||||||
RNU7-47P* | Pre-mRNA intron splicing regulation | − 1.70 | 0.01 | ||||||
SNORD114-10* | Neurodevelopmental disorders | − 2.34 | 0.001 | ||||||
SNORA13* | rRNA modification | 2.24 | 0.001 | 2.3 | 0.001 | 1..85 | 0.001 | 2.25 | 0.001 |
SUSD1* | Epigenetic signature | 2.42 | 0.001 | ||||||
TRHR* | Serotoninergic neurotransmission | − 3.48 | 0.001 |
fc, fold change; *Verified by RT-qPCR; **Verified by Stem-loop RT-qPCR.
HC, hippocampus.